Pointe Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $455K | Sell |
2,977
-161
| -5% | -$24.7K | 0.23% | 96 |
|
|
2025
Q4 | $433K | Sell |
3,138
-484
| -13% | -$63.4K | 0.21% | 102 |
|
|
2025
Q3 | $464K | Hold |
3,622
| – | – | 0.23% | 98 |
|
|
2025
Q2 | $438K | Buy |
3,622
+24
| +0.7% | +$2.71K | 0.23% | 102 |
|
|
2025
Q1 | $401K | Hold |
3,598
| – | – | 0.23% | 103 |
|
|
2024
Q4 | $350K | Buy |
3,598
+56
| +2% | +$5.97K | 0.2% | 114 |
|
|
2024
Q3 | $407K | Sell |
3,542
-300
| -8% | -$34K | 0.24% | 105 |
|
|
2024
Q2 | $409K | Hold |
3,842
| – | – | 0.25% | 101 |
|
|
2024
Q1 | $372K | Sell |
3,842
-352
| -8% | -$36.1K | 0.23% | 108 |
|
|
2023
Q4 | $423K | Buy |
4,194
+43
| +1% | +$4.15K | 0.29% | 90 |
|
|
2023
Q3 | $423K | Buy |
4,151
+21
| +0.5% | +$2.13K | 0.31% | 79 |
|
|
2023
Q2 | $417K | Buy |
4,130
+56
| +1% | +$5.6K | 0.31% | 83 |
|
|
2023
Q1 | $375K | Sell |
4,074
-24
| -0.6% | -$2.1K | 0.27% | 92 |
|
|
2022
Q4 | $372K | Sell |
4,098
-200
| -5% | -$16.8K | 0.29% | 90 |
|
|
2022
Q3 | $327K | Buy |
4,298
+54
| +1% | +$4.48K | 0.26% | 96 |
|
|
2022
Q2 | $359K | Hold |
4,244
| – | – | 0.27% | 94 |
|
|
2022
Q1 | $372K | Buy |
4,244
+446
| +12% | +$38.6K | 0.24% | 109 |
|
|
2021
Q4 | $332K | Buy |
3,798
+150
| +4% | +$12.5K | 0.2% | 116 |
|
|
2021
Q3 | $298K | Buy |
3,648
+40
| +1% | +$3.6K | 0.21% | 115 |
|
|
2021
Q2 | $329K | Buy |
3,608
+125
| +4% | +$11.1K | 0.23% | 110 |
|
|
2021
Q1 | $298K | Sell |
3,483
-66
| -2% | -$5.92K | 0.21% | 112 |
|
|
2020
Q4 | $335K | Sell |
3,549
-141
| -4% | -$12.3K | 0.29% | 100 |
|
|
2020
Q3 | $321K | Buy |
3,690
+120
| +3% | +$10.4K | 0.28% | 97 |
|
|
2020
Q2 | $312K | Hold |
3,570
| – | – | 0.28% | 100 |
|
|
2020
Q1 | $294K | Sell |
3,570
-266
| -7% | -$23.7K | 0.29% | 93 |
|
|
2019
Q4 | $363K | Sell |
3,836
-15
| -0.4% | -$1.35K | 0.3% | 95 |
|
|
2019
Q3 | $335K | Sell |
3,851
-28
| -0.7% | -$2.51K | 0.28% | 103 |
|
|
2019
Q2 | $354K | Sell |
3,879
-594
| -13% | -$50.3K | 0.29% | 100 |
|
|
2019
Q1 | $385K | Sell |
4,473
-75
| -2% | -$6.02K | 0.32% | 91 |
|
|
2018
Q4 | $350K | Sell |
4,548
-52
| -1% | -$4.05K | 0.34% | 86 |
|
|
2018
Q3 | $355K | Buy |
4,600
+513
| +13% | +$37.9K | 0.28% | 106 |
|
|
2018
Q2 | $277K | Buy |
4,087
+858
| +27% | +$59.2K | 0.24% | 119 |
|
|
2018
Q1 | $234K | Buy |
3,229
+56
| +2% | +$4.26K | 0.2% | 136 |
|
|
2017
Q4 | $239K | Sell |
3,173
-166
| -5% | -$12.5K | 0.19% | 136 |
|
|
2017
Q3 | $257K | Buy |
+3,339
| New | +$252K | 0.19% | 137 |
|
|
2016
Q3 | – | Sell |
-2,975
| Closed | -$220K | – | 151 |
|
|
2016
Q2 | $220K | Buy |
+2,975
| New | +$206K | 0.16% | 138 |
|
|
2016
Q1 | – | Sell |
-2,890
| Closed | -$223K | – | 142 |
|
|
2015
Q4 | $223K | Sell |
2,890
-2,192
| -43% | -$174K | 0.16% | 134 |
|
|
2015
Q3 | $419K | Sell |
5,082
-61
| -1% | -$5.43K | 0.26% | 104 |
|
|
2015
Q2 | $453K | Buy |
5,143
+139
| +3% | +$12.8K | 0.2% | 108 |
|
|
2015
Q1 | $442K | Buy |
+5,004
| New | +$444K | 0.21% | 92 |
|
Other funds holding NVS
Pointe Capital Management's NVS Position: Q1 2026 in Review
Pointe Capital Management reduced its Novartis (NVS) stake by 5.1% in Q1 2026, selling an estimated $24.7K and leaving 2,977 shares worth $455K. The position accounts for 0.23% of the portfolio, ranked #96.
Pointe Capital Management first reported a position in NVS in Q1 2015 and has held it in 40 quarters since. The position peaked at $464K in Q3 2025. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Pointe Capital Management held 2,977 shares of Novartis worth $455K as of Q1 2026.
- Pointe Capital Management sold 161 Novartis shares in Q1 2026, an estimated $24.7K.
- Novartis made up 0.23% of Pointe Capital Management's portfolio in Q1 2026, its #96 holding.
- Pointe Capital Management first reported a position in Novartis in Q1 2015 and has held it in 40 quarters since.
- Pointe Capital Management's Novartis position peaked at $464K in Q3 2025.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Pointe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.